Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valproic Acid for I/R Injury in Trauma
NCT04531579Phase 2Withdrawn
- Sponsor
- Westat
- Start
- Jan 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valproic acid in ischemia-reperfusion injury (IRI), acute kidney injury (AKI), sponsored by Westat. Planned start Jan 2022; status: withdrawn.
02
Drugs
valproic acid
03
Conditions
ischemia-reperfusion injury (IRI)acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04531579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531579.